Cytoreductive Nephrectomy and RCC Biomarkers: What’s Next in Kidney Cancer Treatment?

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium, a panel of experts discussed the latest research, emerging therapies, and best practices for treating renal cell carcinoma (RCC). Moderator Dr. Katy Beckermann of Tennessee Oncology was joined by Drs. David Braun, Matt Campbell, Brad McGregor, and Katie S. Murray in the discussion.

In part four, the panelists examine how cytoreductive nephrectomy fits into RCC treatment while assessing the growing influence of biomarkers on decision-making. The discussion covers the best timing for surgery, the effects of systemic therapy, and new approaches aimed at enhancing patient outcomes. Finally, the panel highlights advancements in imaging techniques and ongoing research into bone metastases for improved disease evaluation.

#cancer #cancerresearch #urology #renalcellcarcinoma #asco
Category
Urology
Be the first to comment

Up Next